Skip to content
Skyrizi(risankizumab)
Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis and psoriatic arthritis. It is known to target interleukin-23 subunit alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Skyrizi
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Risankizumab
Tradename
Proper name
Company
Number
Date
Products
Skyrizirisankizumab-rzaaAbbVieN-761105 RX2021-04-26
6 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
skyriziBiologic Licensing Application2020-12-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
psoriasisEFO_0000676D011565L40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC18: Risankizumab
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L4024183229
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K50124—18
Psoriatic arthritisD015535EFO_0003778L40.5122——5
Ulcerative colitisD003093EFO_0000729K51112—14
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1—1———1
Hidradenitis suppurativaD017497L73.2—1———1
DermatitisD003872HP_0011123L30.9—1———1
AsthmaD001249EFO_0000270J45—1———1
Ankylosing spondylitisD013167EFO_0003898M45—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—9————9
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRISANKIZUMAB
INNrisankizumab
Description
Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1612838-76-2
RxCUI2166040
ChEMBL IDCHEMBL3990029
ChEBI ID—
PubChem CID—
DrugBankDB14762
UNII ID90ZX3Q3FR7 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
IL23A
IL23A
Organism
Homo sapiens
Gene name
IL23A
Gene synonyms
SGRF
NCBI Gene ID
51561
Protein name
interleukin-23 subunit alpha
Protein synonyms
IL-23 subunit alpha, IL-23-A, IL-23p19, interleukin 23 p19 subunit, interleukin 23, alpha subunit p19, Interleukin-23 subunit p19, interleukin-six, G-CSF related factor, JKA3 induced upon T-cell activation
Uniprot ID
Q9NPF7
Mouse ortholog
Il23a (83430)
interleukin-23 subunit alpha (Q9EQ14)
Variants
Clinical Variant
No data
Financial
Skyrizi - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,316 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
890 adverse events reported
View more details